BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$874.84MFY2025, +31.1% a year since FY2011